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AbstrACt
Objectives To compare the management, maternal and 
perinatal outcomes of women with a body mass index 
(BMI) ≥60 kg/m2 with women with a BMI >50–59.9 kg/m2.
Design International collaborative cohort study.
setting Binational study in the UK and Australia.
Participants UK: all pregnant women, and Australia: 
women who gave birth (birth weight ≥400 g or gestation 
≥20 weeks)
Methods Data from the Australasian Maternity Outcomes 
Surveillance System and UK Obstetric Surveillance 
System. Management, maternal and infant outcomes were 
compared between women with a BMI ≥60 kg/m2 and 
women with a BMI >50–59.9 kg/m2, using unconditional 
logistic regression.
results The sociodemographic characteristics and 
previous medical histories were similar between the 111 
women with a BMI ≥60 kg/m2 and the 821 women with 
a BMI >50–59.9 kg/m2. Women with a BMI ≥60 kg/m2 
had higher odds of thromboprophylaxis usage in both the 
antenatal (24% vs. 12%; OR 2.25, 95% CI 1.39 to 3.64) 
and postpartum periods (78% vs. 66%; OR 1.68, 95% CI 
1.04 to 2.70). Women with BMI ≥60 kg/m2 had nearly 
double the odds of pre-eclampsia/eclampsia (adjusted 
OR 1.83 (95% CI 1.01 to 3.30)). No other maternal or 
perinatal outcomes were statistically significantly different. 
Severe adverse outcomes such as perinatal death were 
uncommon in both groups thus limiting the power of these 
comparisons. The rate of perinatal deaths was 18 per 
1000 births for those with BMI ≥60 kg/m2; 12 per 1000 
births for those with BMI >50–59.9 kg/m2; those with 
BMI ≥60 kg/m2 had a non-significant increased odds of 
perinatal death (unadjusted OR 1.46, 95% CI 0.31 to 6.74).
Conclusions Women are managed differently on 
the basis of BMI even at this extreme as shown by 
thromboprophylaxis. The pre-eclampsia result suggests 
that future research should examine whether weight 
reduction of any amount prior to pregnancy could reduce 
poor outcomes even if women remain extremely obese.
IntrODuCtIOn 
Obesity is a major risk factor for non-com-
municable disease and morbidity in later 
life. It has reached epidemic levels in many 
high-income settings across all age ranges. 
Obesity is defined as a body mass index (BMI) 
of ≥30 kg/m2. Increasing rates of obesity in 
the general population are associated with 
an increasing trend towards obesity in preg-
nancy.1 Within the general population, the 
largest increases in obesity have been in the 
highest BMI groups2 and this is also true for 
extreme obesity in pregnancy.3 
Maternal obesity is a risk factor for a 
number of pregnancy-related complications 
and its relationship with these complica-
tions are complex.4 5 These relationships can 
be partially explained through pre-existing 
comorbidities such as diabetes,6 hyperten-
sion6 7 and asthma.6 Pre-existing comorbidi-
ties have been shown to increase the risk of 
pre-eclampsia8 9 and venous thromboembolic 
events.10 However, there remain other mech-
anisms that explain the association between 
obesity and pre-eclampsia/venous thrombo-
embolism; to specify a few, these are inflam-
mation,11 insulin resistance12 and oxidative 
stress.13 14
Several studies have investigated the prev-
alence, outcomes and managements of 
extreme obesity in pregnancy (BMI ≥50 kg/
m2).15–17 These have aimed to test whether 
there was a dose–response relationship 
between increased BMI and complications 
strengths and limitations of this study
 ► Population-based study examining extreme obesity 
using national data from the UK and Australia.
 ► International collaborative studies allow the exam-
ination of rare exposures.
 ► This study lacked the power to examine many ma-
ternal and perinatal outcomes despite having data 
from two national studies
 ► Some outcomes were not comparable between 
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of pregnancy. Within the extremely obese group (BMI 
≥50 kg/m2), women included have had a BMI ranging 
from ≥50 kg/m2 to approximately 75 kg/m2. While it may 
be the case that the risks rise exponentially with BMI, it 
is possible that above a certain BMI, the risks of maternal 
and perinatal complications as a result of obesity do not 
increase due to the competing risks of other comorbidi-
ties. This remains to be investigated, as current published 
data do not allow the division of women into the highest 
BMI groups.
Previous research pooling together international data 
on rare exposures in pregnancy has been limited due to 
heterogeneity of definitions, methods and populations.18 
The obstetric surveillance systems in Australia and the UK 
were designed to be compatible with data collection using 
similar definitions with a view to pooling data. As a result, 
there are comparable data available to combine national 
studies, which provides a large enough sample to compare 
two groups of women within a cohort of extremely obese 
women. This study aimed to compare the characteristics, 
management (including guideline adherence for preven-
tion of venous thromboembolism), and maternal and 
perinatal outcomes of women at the extremes of obesity.
MethODs
study population and design
This study was an international population-based cohort 
study, using secondary analysis of two national cohort 
studies of extreme maternal obesity, which were under-
taken in Australia and the UK.16 19 For the purposes of 
the analysis, the exposed cohort were those pregnant 
women who had a BMI ≥60 kg/m2 and the unexposed 
comparison cohort were those with a BMI >50–59.9 kg/
m2. Woman were included in the study if they had a BMI 
>50 kg/m2 at any point during the pregnancy and were 
included as part of the respective national studies.16 19
Anonymous data were prospectively collected using the 
respective national obstetric surveillance system, the UK 
Obstetric Surveillance System (UKOSS) or the Austral-
asian Maternity Outcomes Surveillance System (AMOSS). 
The methods of each system have been described else-
where in detail.19–21 Briefly, in the UK, nominated 
reporters within each consultant-led obstetric unit 
received a monthly mailing card; the card had a tick box 
to indicate whether there had been a case of extreme 
obesity that month. There was also a box to indicate that 
there were no cases. Reporters returned cards regard-
less of whether there had been a case of extreme obesity. 
When a case was notified the reporter received a data 
collection form. Using the medical records of the patient, 
information on demographic characteristics, obstetric 
history, medical history (including height and weight), 
management and outcomes were collected.
A similar method was used to identify women with 
extreme obesity in Australia. Designated reporters within 
each participating maternity unit within Australia were 
sent a monthly email. The reporter either responded with 
a ‘case’ or a ‘nil case’ to indicate whether there had truly 
been no cases. Once a case was reported, the reporter 
entered data on an online data collection form using the 
case notes of the woman. The AMOSS system had 66% 
coverage of all women giving birth in Australia during the 
study.19
Outcomes, management and potential covariates rele-
vant to the research question were identified from the 
literature. On the basis of this, possible covariates and 
outcomes were identified in the respective UKOSS and 
AMOSS data sets. Each variable was mapped between the 
AMOSS and UKOSS data sets and an assessment of the 
comparability was made. On occasions, where the coding 
differed, harmonisation of the coding was devised and 
applied. This resulted in uniform values and labels of 
variables across both data sets. An assessment was made 
to determine whether the variables were measuring the 
same clinical phenotype in similar ways.
The covariates explored in the analysis were age, 
smoking status during pregnancy, previous pregnancy 
problems, pre-existing medical problems, pre-existing 
hypertension, parity and multiple pregnancies.
The missing data in similar data sets have been shown 
not to be missing at random; as a result, multiple imputa-
tion was not considered appropriate.22 A missing category 
was created for each variable to account for the missing 
data. Primarily, complete case analysis was used in the 
multivariable analysis and a sensitivity analysis including 
the missing categories was used to assess the impact of 
missing data on the point estimates.
The sample size was predetermined by the size of the 
existing studies; therefore, the sample was fixed at 111 
women who had a BMI ≥60 kg/m2 and 821 women who 
had a BMI >50–59.9 kg/m2. For the lowest frequency 
outcome (perinatal death), which had an incidence of 
1.2% in the unexposed group, given the sample size, the 
minimum OR detectable as statistically significant with 
80% power at the 5% significance level was 5.63. For the 
highest frequency outcome, which had an incidence of 
66.4% (thromboprophylaxis postnatally) in the unex-
posed group, the minimum OR detectable as statistically 
significant with 80% power at the 5% significance level 
was 1.99.
statistical analysis
Descriptive analyses were undertaken using the χ2 test or 
Wilcoxon rank sum test as appropriate. These analyses 
assessed whether there was a statistical difference in char-
acteristics between those women who had a BMI ≥60 kg/
m2 and those with a BMI >50–59 kg/m2.
Each outcome was individually modelled in a univari-
able analysis using unconditional logistic regression, 
with results presented as unadjusted OR (uOR) with 
95% CI. The exposure variable in each model was 
extreme obesity BMI ≥60 kg/m2. To account for clus-
tering of infants within mothers (multiple births), robust 
estimates of variance were calculated. Collinearity was 
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to multivariable analysis, using Pearson’s correlation 
coefficient.
Only outcomes that were statistically significant at 
the univariable level were included in the multivariable 
analysis. In the multivariable analysis, potential explana-
tory variables were sequentially added to the univariable 
model in a forward stepwise method with an examina-
tion of the results as each variable was added. A plausible 
explanatory variable was included in the final model if it 
was associated with the exposure and outcome (p value 
for Wald test <0.05) andsignificantly improved the model 
fit assessed by likelihood ratio tests at the 5% significance 
level. Statistical analysis was completed using STATA V.13.
A post hoc analysis was completed to assess the risk 
factors for venous thromboembolism possessed by those 
who did not receive postnatal thromboprophylaxis. This 
was a country-specific analysis using risk factors of venous 
thromboembolism which were identified from the Royal 
College of Obstetricians and Gynaecologists (RCOG) and 
South Australian Maternal & Neonatal Clinical Network 
guidelines.23 24
Patient and public involvement statement
There is patient and public involvement (PPI) involve-
ment in the UKOSS steering committee through lay 
members. The UKOSS steering committee assisted in the 
study design and management of the study. The AMOSS 
advisory group has PPI involvement through consumer, 
Maori and Pacific and Aboriginal and Torres Strait 
Islander members. The AMOSS advisory group provides 
advice on the implementation, delivery and development 
of the AMOSS system. The group also assists with the 
translation of findings into practice.
ethics committee approval
The Australian collaborators obtained approval for the 
study.25 Ethics committee approval for secondary analysis 
of anonymous UK data was not required.
results
During the period of September 2007–August 2008, 617 
women with a BMI >50 kg/m2 were identified through the 
UKOSS. Between January and October 2010, 315 women 
with a BMI >50 kg/m2 were identified using the AMOSS. 
Overall, there were 111 women with a BMI ≥60 kg/m2 
and 821 women with a BMI >50–59.9 kg/m2.
Women with a BMI ≥60 kg/m2 were slightly older, the 
sociodemographic characteristics and previous medical 
histories were otherwise similar in the two groups of 
women (table 1).
A high proportion in both groups experienced diffi-
culties in visualisation of ultrasound (70.3% vs 65.7%) 
although this was not statistically significant between 
the groups. Fewer women in both groups received ante-
natal thromboprophylaxis (24.3% BMI ≥60 kg/m2 and 
12.3%>50–59.9 kg/m2) compared with postnatal throm-
boprophylaxis (77.5% and 66.4%) (table 2). Women with 
a BMI ≥60 kg/m2 had a significantly higher odds of pre-ec-
lampsia/eclampsia (uOR 1.91 (95% CI 1.08 to 3.39)), 
and of receiving either thromboprophylaxis antenatally 
(uOR 2.25 (95% CI 1.39 to 3.64)) or postnatally (uOR 
1.68 (95% CI 1.04 to 2.70)) compared with those with 
a BMI >50–59.9 kg/m2 (table 2). Online supplementary 
tables 1 and 2 show that approximately a third of women 
should have received thromboprophylaxis postnatally 
in both the UK and Australia as they had the relevant risk 
factors for it to be indicated.
Although not statistically significant, a higher propor-
tion of women with a BMI ≥60 kg/m2 experienced 
other adverse outcomes other than pre-eclampsia/
eclampsia. Pre-eclampsia/eclampsia was examined in 
a multivariable model. The presence of a BMI ≥60 kg/
m2 was associated with a twofold increase in the odds of 
having pre-eclampsia/eclampsia (adjusted OR (aOR) 
1.83 (95% CI 1.01 to 3.30)) compared with those with 
a BMI >50–59 kg/m2, after adjusting for smoking status, 
pre-existing diabetes and parity. The results of the proxy 
variable model did not materially differ from those of the 
complete case analysis.
Severe adverse outcomes such as perinatal death were 
uncommon in both groups (n=2 (18 per 1000 births), BMI 
≥60 kg/m2 vs n=10 (12 per 1000 births), BMI ≥50–59 kg/
m2). There were no statistically significant differences 




Compared with women with a BMI >50–59 kg/m2, 
women with a BMI ≥60 kg/m2 had an increased risk of 
pre-eclampsia/eclampsia, There were very few statistically 
significant differences in outcomes between the two very 
high BMI groups. Nevertheless, the direction of effects 
favours the lower BMI group for most outcomes. Further 
research should test whether any weight reduction could 
reduce poor outcomes even if women remain extremely 
obese. Importantly, the perinatal mortality rate was 
higher in both groups compared with the national UK 
and Australian rates of perinatal mortality. Women are 
being managed differently on the basis of BMI even at 
this extreme as use of thromboprophylactic drugs varied 
between the two high BMI groups.
strengths and limitations
Both prospective population-based surveillance systems 
use a robust methodology, which reduces the risk of selec-
tion bias. Two national studies allowed the examination of 
women with a BMI ≥60 kg/m2 in a high resource setting 
and thus overcomes some of the limitations of previous 
research, which was limited by the number of women in 
the extreme ends of the BMI distribution. Nevertheless, 
despite pooling of national data, the number of women 
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Table 1 Sociodemographic characteristics and previous medical problems in women with body mass index (BMI) ≥60 kg/m2 
and comparison women (BMI >50–59.9 kg/m2)
Characteristic
Number (%) of obese 
women with BMI ≥60 
kg/m2 (n=111)
Number (%) of women 
with BMI 50–59.9 kg/
m2 (n=821) P values
Sociodemographic characteristics
  Age Mean (Std) 31.7 (5.51) 30.3 (5.67) 0.017
  BMI at booking Median (IQR) 61.7 (60–64.9) 52.3 (50.8–54.9) <0.001
  Max recorded BMI Median (IQR) 62.9 (61–66.8) 52.7 (50.9–55.0) <0.001
  Smoking status Never/ex-smoker 85 (76.6) 599 (73) 0.42
Smoked during pregnancy 24 (21.6) 206 (25.1)
Missing 2 (1.8) 16 (1.9)
Known previous medical history
  Previous pregnancy problems None 41 (36.9) 273 (33.3) 0.713
Yes 33 (29.7) 266 (32.4)
Primigravid 35 (31.5) 271 (33.0)
Missing 2 (1.8) 11 (1.3)
  Known cardiac disease None 109 (98.2) 812 (98.9) 0.2*
Yes 2 (1.8) 5 (0.6)
Missing 0 (0) 4 (0.5)
  Known renal disease None 110 (99.1) 809 (98.5) 0.999*
Yes 1 (0.9) 8 (1.0)
Missing 0 (0) 4 (0.5)
  Known mental health issues None 99 (89.2) 756 (92.1) 0.219
Yes 12 (10.8) 61 (7.4)
Missing 0 (0) 4 (0.5)
  Known asthma None 98 (88.3) 720 (87.7) 0.961
Yes 13 (11.7) 97 (11.8)
Missing 0 (0) 4 (0.5)
  Previous caesarean delivery None 53 (47.7) 366 (44.6) 0.297
Yes 22 (19.8) 181 (22.0)
 Primigravid 35 (31.5) 271 (33.0)
Missing 1 (0.9) 3 (0.4)
  Parity Nulliparous 35 (31.5) 271 (33) 0.803
Multiparous 75 (67.6) 550 (67)
Missing 1 (0.9) 0 (0)
Current pregnancy
  Multiple pregnancy Singleton 108 (97.3) 800 (97.4) 0.928
Twin pregnancy 3 (2.7) 21 (2.6)
  Known hypertension prior to 
pregnancy requiring treatment
None 103 (92.8) 767 (93.4) 0.693
Yes 8 (7.2) 51 (6.2)
Missing 0 (0) 3 (0.4)
  Known pre-existing diabetes 
prior to pregnancy
None 101 (91.0) 757 (92.2) 0.657
Yes 10 (9.0) 64 (7.8)
Missing – – 
  Insulin-dependent diabetes Yes 4 (3.6) 17 (2.1) 0.705* 
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the study power, particularly when investigating rare 
outcomes.
This study did not have access to ethnicity from 
Australia and socioeconomic measures were not compa-
rable between the countries. Thus, the aOR presented 
may be vulnerable to residual confounding if ethnicity 
and socioeconomic status were associated with both the 
outcome and exposure.
This analysis aimed only to compare the preg-
nancy outcomes of two groups of extremely obese 
women, and does not therefore provide any informa-
tion on the outcomes of these extremely obese preg-
nant women in comparison to pregnant women with 
BMIs within the normal range. Comparisons with preg-
nant women who have a lower BMI have been previously 
published.16 19
Table 2 Maternal outcomes and management in women with body mass index (BMI) ≥60 kg/m2 and comparison women (BMI 
>50–59.9 kg/m2)
Number (%) of 
women with BMI 
≥60 kg/m2 (n=111)
Number (%) of women 
with BMI >50–59.9 kg/
m2 (n=821)
Unadjusted 
OR 95% CI P values
Management
  Difficulties undertaking 
ultrasounds
No 30 (27) 228 (27.8) 1
Yes 78 (70.3) 539 (65.7) 1.1 (0.70 to 1.72) 0.678
Missing 3 (2.7) 54 (6.6)
  Induced No 70 (63.1) 505 (61.5) 1
Yes 40 (36) 303 (36.9) 0.95 (0.63 to 1.44) 0.817
Missing 1 (0.9) 13 (1.6)
  Caesarean delivery No 48 (43.2) 398 (48.5) 1
Yes 62 (55.9) 411 (50.1) 1.25 (0.84 to 1.87) 0.274
Missing 1 (0.9) 12 (1.5)
  Thromboprophylaxis usage 
in antenatal period
No 84 (75.7) 706 (86) 1
Yes 27 (24.3) 101 (12.3) 2.25 (1.39 to 3.64) 0.001
Missing 0 (0) 14 (1.7)
  Thromboprophylaxis usage 
in postpartum period
No 24 (21.6) 255 (31.1) 1
Yes 86 (77.5) 545 (66.4) 1.68 (1.04 to 2.70) 0.033
Missing 1 (0.9) 21 (2.6)
Maternal outcome
  Wound infection in those 
with caesarean
No 47 (42.3) 344 (41.9) 1
Yes 14 (12.6) 57 (6.9) 1.8 (0.93 to 3.48) 0.081
N/A 49 (44.1) 410 (49.9)
Missing 1 (0.9) 10 (1.2)
  Venous thromboembolism No 111 (100) 807 (98.3)
Yes 0 (0) 7 (0.9) 0 (0.0 to 4.00) 0.325
Missing 0 (0) 7 (0.9)
  Hypertensive disorder 
during pregnancy
No 77 (69.4) 631 (76.9) 1
Yes 33 (29.7) 183 (22.3) 1.48 (0.95 to 2.29) 0.082
Missing 1 (0.9) 7 (0.9)
  Pregnancy-induced 
hypertension
No 94 (84.7) 702 (85.5) 1
Yes 16 (14.4) 112 (13.6) 1.07 (0.61 to 1.88) 0.823
Missing 1 (0.9) 7 (0.9)
  Pre-eclampsia/eclampsia No 93 (83.8) 743 (90.5) 1
Yes 17 (15.3) 71 (8.6) 1.91 (1.08 to 3.39) 0.026
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Interpretation
One of the novel benefits of this multinational study was 
the ability to examine a subset of the more extreme end of 
the spectrum of obesity. This demonstrated that women 
with a BMI ≥60 kg/m2 had very similar characteristics and 
experienced similar management compared with women 
with a BMI >50 to <60 kg/m2. Interestingly, BMI ≥60 kg/m2 
group had an increased risk of pre-eclampsia/eclampsia, 
which supports the hypothesis of a ‘dose response’ rela-
tionship between obesity and pre-eclampsia/eclampsia 
seen at lower BMIs26 and super obesity.17 27
The comparison of extreme maternal obesity and 
a representative BMI group has been previously 
studied.16 19 The risk of pre-eclampsia, venous throm-
boembolism, preterm delivery, shoulder dystocia and 
caesarean delivery was elevated in women with extreme 
maternal obesity compared with non-extremely obese 
women.16 19 Despite few statistically significant differences 
in outcomes between the two groups, the literature high-
lights that the risk is substantially higher for extremely 
obese women compared with women in a normal BMI 
group.
Table 3 Perinatal outcomes in women with body mass index (BMI) ≥60 kg/m2 and comparison women (BMI >50–59.9 kg/m2)
Number (%) of 
women with BMI 
≥60 kg/m2
Number (%) of 
women with BMI 
>50–59.9 kg/m2
Unadjusted 
OR 95% CI P Values
Perinatal death* No 112 (98.2) 815 (98.5) 1
Yes 2 (1.8) 10 (1.2) 1.46 (0.31 to 6.74) 0.631
Missing 0 (0) 2 (0.2)
Stillbirth ≥24 weeks 
gestation*
No 112 (98.2) 818 (98.9) 1
Yes 2 (1.8) 7 (0.8) 2.09 (0.43 to 10.19) 0.363
Missing 0 (0) 2 (0.2)
Preterm birth No 101 (90.2) 730 (89) 1
Yes 10 (8.9) 87 (10.6) 0.83 (0.36 to 1.94) 0.668
Missing 1 (0.9) 3 (0.4)
Very preterm birth No 111 (99.1) 804 (98) Omitted
Yes 0 (0) 13 (1.6)
Missing 1 (0.9) 3 (0.4)
Birth weight Mean (Std) 3683.0 (752.1) 3603.7 (715.0) Omitted
Macrosomia (>4500 g) No 98 (87.5) 746 (91.0) 1
Yes 14 (12.5) 72 (8.8) 1.48 (0.80 to 2.73) 0.211
Missing 0 (0) 2 (0.2)
Shoulder dystocia No 44 (39.3) 373 (45.5) 1
Yes 1 (0.9) 19 (2.3) 0.45 (0.06 to 3.42) 0.438
Not applicable 66 (58.9) 424 (51.7)
Missing 1 (0.9)  4 (0.5)
Congenital abnormality No 107 (95.5) 797 (97.2) 1
Yes 3 (2.7) 13 (1.6) 1.72 (0.48 to 6.14) 0.404
Missing 2 (1.8) 10 (1.2)
Infant respiratory 
problem
No 109 (97.3) 797 (97.2) 1
Yes 3 (2.7) 18 (2.2) 1.22 (0.35 to 4.21) 0.755
Missing 0 (0) 5 (0.6)
Apgar score <7 at 5 min No 105 (93.8) 778 (94.9) 1
Yes 2 (1.8) 25 (3.0) 0.59 (0.14 to 2.54) 0.482
Missing 5 (4.5) 17 (2.1)
OR estimated using robust standard errors.
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The BMI ≥60 kg/m2 cohort had a higher proportion of 
perinatal deaths and stillbirths than the BMI >50–59.9 kg/
m2 cohort, although these were not statistically signifi-
cantly different possibly because of the small numbers 
involved. The absolute rate of perinatal death for the 
≥60 kg/m2 cohort was three times higher than the UK 
rate (5.6 per 1000 births) and 2.5 times higher than the 
Australian rate (7.3 per 1000); while the rate of perinatal 
mortality in the >50–59.9 kg/m2 cohort was just over twice 
that of the UK rate and was 1.5 times higher than the 
Australian perinatal mortality rate.28 29
A previous study of extreme obesity that examined peri-
natal outcomes has suggested that there is a dose–response 
relationship between BMI and perinatal outcomes.17 The 
small sample size and relative rarity of adverse perinatal 
outcomes in this analysis did not allow the role of chance 
to be excluded for most outcomes, even with pooling 
of two national studies.
The results of this study show that the degree of rela-
tive obesity impacted on thromboprophylaxis prac-
tice. The RCOG’s guideline states that any women with 
a BMI >40 kg/m2 should be considered at intermediate 
risk of venous thromboembolism and should be given 
at least 10 days of thromboprophylaxis postnatally.23 
Within Australia, there is regional variation in the guide-
lines concerning BMI and postpartum thromboprophy-
laxis. The Queensland state guideline suggests that a 
woman must possess three or more risk factors (BMI 
>30 kg/m2 being one of these risk factors) to be given 
low molecular weight heparin for 6 days postnatally, 
while the South Australian government and current 
expert opinion recommends that BMI ≥30 kg/m2 plus 
one major risk factor for thromboembolism requires 
prophylactic anticoagulation for 5 days postpartum.24 30 
Data from this study suggest guidelines appear to be 
followed variably due to the large variation in practice 
between the two cohorts. This suggests more implemen-
tation work within clinical settings is needed to help 
these guidelines be followed. Nevertheless, the results 
show that BMI has an important impact on clinical deci-
sions concerning the administration of thromboprophy-
laxis postnatally.
Importantly, approximately 75% had postnatal throm-
boprophylaxis, which is smaller than expected consid-
ering this was an extremely obese population. Nearly a 
third of women in both countries had the appropriate risk 
factors to indicate the use of thromboprophylaxis postna-
tally. This highlights an important area for improvement 
of clinical practice to prevent a potentially fatal venous 
thromboembolism.
Interestingly, there were no venous thromboembolic 
events in the BMI ≥60 kg/m2 group, which was the 
group in which the larger proportion of women received 
thromboprophylaxis, although, again, these are very rare 
events. Previous studies have shown that BMI is a strong 
risk factor of venous thromboembolism31 32 and the risk 
is amplified in those who have a high BMI and were 
immobilised.33
This study was a secondary data analysis of women iden-
tified during 2008 in the UK and 2010 in the Australia. 
As a result, it is likely that the proportion of women who 
have a BMI >50 since the original studies is likely to be 
much larger, which makes the findings of this study even 
more pertinent.
Conclusions
There were very few statistically significant differences in 
outcomes between these two high BMI groups. However, 
the direction of effect favours the lower BMI group for 
most outcomes and a type II error cannot be excluded 
given the small number of women/infants within each 
outcome. Pre-eclampsia risk is increased with increasing 
BMI in the morbidly obese women. Further research 
should test whether any weight reduction could reduce 
poor outcomes even if women remain extremely obese. 
Women are clearly being managed differently on the basis 
of BMI even at this extreme as shown by the thrombopro-
phylaxis data. Furthermore, there was a failure to apply 
thromboprophylaxis guidelines fully in 2007–2008 which 
emphasises a need to ensure women at risk of venous 
thromboembolism receive appropriate prevention care.
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